Current Radiopharmaceuticals
Title:Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease)
Volume: 8 Issue: 2
Author(s): Furn F. (Russ) Knapp and Ambikalmajan M.R. Pillai
Affiliation:
Export Options
About this article
Cite this article as:
(Russ) Knapp F. Furn and Pillai M.R. Ambikalmajan, Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease), Current Radiopharmaceuticals 2015; 8 (2) . https://dx.doi.org/10.2174/1874471008666150312124009
DOI https://dx.doi.org/10.2174/1874471008666150312124009 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Activin Receptor-Like Kinases: Structure, Function and Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
Current Pharmaceutical Design From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Endocrine, Metabolic & Immune Disorders - Drug Targets Ligand-Based Computer-Aided Discovery of Tyrosinase Inhibitors. Applications of the TOMOCOMD-CARDD Method to the Elucidation of New Compounds
Current Pharmaceutical Design Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery The Flavin-Containing Monoooxygenases (FMOs): Genetic Variation and its Consequences for the Metabolism of Therapeutic Drugs
Current Pharmacogenomics Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Anti-Cancer Agents in Medicinal Chemistry Critical Residues in Hsp70 Nucleotide Binding Domain for Challenges in Drug Design
Current Proteomics Urea Derivatives as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Platelet Biomarkers in Tumor Growth
Current Proteomics Recent Advances in Antiangiogenic Agents with VEGFR as Target
Mini-Reviews in Medicinal Chemistry Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy
Current Pharmaceutical Design Complexities of Glucuronidation Affecting In Vitro-In Vivo Extrapolation
Current Drug Metabolism The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Preclinical Toxicity of Paclitaxel Biopolymer Formulation
Anti-Cancer Agents in Medicinal Chemistry Amino Acid Transporter-Targeted Radiotracers for Molecular Imaging in Oncology
Current Medicinal Chemistry